immunotherapy

A Global Summit, a Personal Reckoning At the European Society for Medical Oncology (ESMO) Leadership Summit in Singapore, discussions moved rapidly from antibody–drug conjugates to next-generation sequencing and the expanding role of immunotherapy. Clinical trial curves filled large screens, and…

In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…

“I’m a scientist first and foremost. I don’t remember a time not thinking about being a scientist.” What Karen Knudsen, the CEO of Parker Institute for Cancer Immunotherapy, remembers clearly is the pull not toward prestige or power, but toward…

Scientific discovery drives oncology forward, but progress only truly begins when knowledge is turned into action. Every issue of CancerWorld explores the people, ideas, and systems shaping the future of oncology. Scientific breakthroughs remain essential, but their true value emerges…

Chimeric antigen receptor natural killer T (CAR-NKT) cell therapy, a novel form of immunotherapy, is emerging as a promising ‘off-the-shelf’ treatment for patients with pancreatic cancer. In a study published in PNAS, November 21, 2025, U.S. investigators report that CAR-NKT cells…

Each evening, after a day leading one of Italy’s busiest radiotherapy departments, Prof. Andrea Filippi, Head of the Radiation Oncology Unit at the Istituto Nazionale dei Tumori in Milan, and the Associate Professor of Radiation Oncology in the Department of…

Could artificial sweeteners undo the benefits of immunotherapy? A study published in Cancer Discovery, July 30, found that melanoma and non-small cell lung cancer (NSCLC) patients who consume high levels of the artificial sweetener sucralose have worse responses to immunotherapy…

Dr. Nageatte Ibrahim has spent her career at the intersection of oncology, science, and medicine, with achievements resulting in global impacts. Trained as a physician and scientist, she played a central role in the development of Keytruda, one of the…

Selective serotonin reuptake inhibitors (SSRIs) enhanced the ability of T cells to fight cancer and suppressed tumour growth across a range of cancer types in both mouse and human tumour models. The study, published in Cell, May 20, further showed…

It was 2018, and I was a fifth-year medical student at Yerevan State Medical University. Word spread that our new oncology professor was someone extraordinary: Gevorg Tamamyan - a Harvard-trained, Nature-published pioneer of pediatric oncology in Armenia and president of…